Phase II Trial of TAS-102 in Colorectal Cancer Patients With Circulating Tumor DNA-Defined Minimal Residual Disease After Adjuvant Therapy: INTERCEPT-TT A multiplex QIF assay was optimized on tissue ...

insights from industryDr. Ruizhi WangFounder and CEOAbselion In this interview, News Medical-Life Sciences speaks with Dr. Ruizhi Wang, Founder and CEO of Abselion, about simplifying the ...